Skip to content
ScienceDirrect

Journal of Taibah University Medical Sciences

Date: 12 October 2026

Volume 21, Issue 5 · Pages: 1199–1207

Show more⌄
Structured Review● Open accessUnder a Creative Commons license ↗
Structured Review

From empirical to phenotype-guided pharmacotherapy of chronic orofacial pain: a structured review and quantitative synthesis of epidemiological, pharmacological, psychophysical and dental evidence

Show more⌄

Abstract

Background Chronic orofacial pain (OFP) comprises musculoskeletal, neuropathic and nociplastic disorders, yet first-line drug selection remains largely empirical and is frequently extrapolated from spinal and peripheral neuropathic pain. Objective To quantify the evidence underpinning pharmacotherapy of the four principal ICOP-2020 disorders and to appraise psychophysical, neurophysiological and dental markers as candidate predictors of treatment response.…

Keywords
orofacial pain; temporomandibular disorders; burning mouth syndrome; trigeminal neuralgia; quantitative sensory testing; conditioned pain modulation; bruxism; personalised pharmacotherapy

Authors and affiliations

Malika M. Giyazova, 0000-0002-9688-3084, Siddik Sh. Olimov

Author affiliations are listed in the full article PDF.

Background

Chronic orofacial pain (OFP) comprises musculoskeletal, neuropathic and nociplastic disorders, yet first-line drug selection remains largely empirical and is frequently extrapolated from spinal and peripheral neuropathic pain.

Objective

To quantify the evidence underpinning pharmacotherapy of the four principal ICOP-2020 disorders and to appraise psychophysical, neurophysiological and dental markers as candidate predictors of treatment response.

Methods

Structured review of PubMed/MEDLINE and Cochrane sources to October 2026 (meta-analyses, randomised controlled trials [RCTs] and large observational cohorts). Estimates were extracted as reported; where only counts or confidence intervals were available, odds/risk ratios with 95% CI and exact two-sided p values were computed (Fisher’s exact test; Altman–Bland method).

Results

Prevalence spanned three orders of magnitude, from 31.1% for temporomandibular joint disorders to 0.03% for persistent idiopathic facial pain. OFP-specific randomised evidence was small (burning mouth syndrome: 23 RCTs, 1,121 participants), whereas neuropathic-pain recommendations rest on 313 trials (48,789 participants) that excluded idiopathic OFP; first-line numbers needed to treat increased between 2015 and 2025 (tricyclics 3.6→4.6; SNRIs 6.4→7.4). Patients with TMD had lower remote pressure pain thresholds (SMD −1.92; p<0.01), and non-paroxysmal OFP showed enhanced temporal summation (SMD 0.30; p=0.002), whereas impaired conditioned pain modulation (CPM) did not reach significance (p=0.066; I²=98%). Mechanism-stratified studies outside the face showed phenotype-dependent efficacy (CPM–duloxetine r=0.628, p<0.001; oxcarbazepine phenotype interaction p=0.047). Bruxism was associated with TMD (OR 2.25; p<0.001), but self-reported sleep bruxism discriminated cases from controls (OR 6.89; p<0.001) whereas polysomnography did not (OR 0.88; p=0.78).

Conclusions

Current evidence supports, but has not yet tested, phenotype-guided first-line drug selection in chronic OFP. Prospective trials combining standardised psychophysics, trigeminal neurophysiology and instrumentally verified dental factors are required; a testable phenotype-to-drug framework is proposed.

Full article

Open the full article PDF

How to cite

Malika M. Giyazova, 0000-0002-9688-3084, Siddik Sh. Olimov. (2026). From empirical to phenotype-guided pharmacotherapy of chronic orofacial pain: a structured review and quantitative synthesis of epidemiological, pharmacological, psychophysical and dental evidence. Journal of Taibah University Medical Sciences, Volume 21, Issue 5, 1199–1207. Article ID: SDR-2026-0029.

All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
RELX